Report of the Report of the
Contents Overview Executive Board Supervisory Board
Financial
statements
Other information
An impairment loss in respect of a financial asset measured at amortised cost is calculated as the difference between its carrying
amount, and the present value of the estimated future cash flows discounted at the original effective interest rate. An impairment
loss in respect of an available-for-sale financial asset is calculated by reference to its current fair value.
Individually significant financial assets are tested for impairment on an individual basis. The remaining financial assets are assessed
collectively in groups that share similar credit risk characteristics.
All impairment losses are recognised in profit or loss. Any cumulative loss in respect of an available-for-sale financial asset recognised
previously in other comprehensive income and presented in the fair value reserve in eguity is transferred to profit or loss.
An impairment loss is reversed if the reversal can be related objectivelyto an event occurring after the impairment loss was recognised.
For financial assets measured at amortised cost and available-for-sale financial assets that are debt securities, the reversal is recognised
in profit or loss. For available-for-sale financial assets that are eguity securities, the reversal is recognised in other comprehensive income.
(ii) Non-financial assets
The carrying amounts of FIEINEKEN's non-financial assets, other than inventories (refer accounting policy (h) and deferred tax assets
(refer accounting policy (s)), are reviewed at each reporting date to determine whether there is any indication of impairment. If any
such indication exists then the asset's recoverable amount is estimated. For goodwill and intangible assets that are not yet available
for use, the recoverable amount is estimated each year at the same time.
The recoverable amount of an asset or CGU is the higher of an asset's fair value less costs to sell and value in use. In assessing value
in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market
assessments of the time value of money and the risks specific to the asset or CGU.
For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of
assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups
of assets (the'CGU').
For the purpose of impairment testing, goodwill acguired in a business combination, is allocated to each of the acguirer's CGUs, or
groups of CGUs, that is expected to benefit from the synergies of the combination. Each unit or group of units to which the goodwill
is allocated represents the lowest level within the entity at which the goodwill is monitored for internal management purposes.
Goodwill is monitored on regional, sub regional or country level depending on the characteristics of theacguisition, the synergies
to be achieved and the level of integration.
An impairment loss is recognised if the carrying amount of an asset or its CGU exceeds its recoverable amount. A CGU is the smallest
identifiable asset group that generates cash flows that largely are independent from other assets and groups. Impairment losses are
recognised in profit or loss. Impairment losses recognised in respect of CGU are allocated first to reduce the carrying amount of any
goodwill allocated to the units and then to reduce the carrying amounts of the other assets in the unit (group of units) on a pro rata
basis. An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognised in prior
periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss
is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed
only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of
depreciation or amortisation, if no impairment loss had been recognised.
Goodwill that forms part of the carrying amount of an investment in an associate and joint venture is not recognised separately, and
therefore is not tested for impairment separately. Instead, the entire amount of the investment in an associate and joint venture is
tested for impairment as a single asset when there is objective evidence that the investment in an associate may be impaired.
Heineken N.V. Annual Report 2013
73
